Key features and details
- Rabbit polyclonal to RANK
- Suitable for: WB
- Reacts with: Mouse, Human
- Isotype: IgG
Product nameAnti-RANK antibody
See all RANK primary antibodies
DescriptionRabbit polyclonal to RANK
SpecificityThis antibody detects endogenous levels of total RANK protein.
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Mouse, Human
Synthetic peptide corresponding to Human RANK (internal sequence). Gene Accession: NP_001257880.
Database link: Q9Y6Q6
- Human liver and mouse kidney tissue lysates.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.4
Preservative: 0.05% Sodium azide
Constituents: 49% PBS, 50% Glycerol (glycerin, glycerine)
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab200369 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/200 - 1/1000. Predicted molecular weight: 66 kDa.|
FunctionReceptor for TNFSF11/RANKL/TRANCE/OPGL; essential for RANKL-mediated osteoclastogenesis. Involved in the regulation of interactions between T-cells and dendritic cells.
Tissue specificityUbiquitous expression with high levels in skeletal muscle, thymus, liver, colon, small intestine and adrenal gland.
Involvement in diseaseDefects in TNFRSF11A are the cause of familial expansile osteolysis (FEO) [MIM:174810]. FEO is a rare autosomal dominant bone disorder characterized by focal areas of increased bone remodeling. The osteolytic lesions develop usually in the long bones during early adulthood. FEO is often associated with early onset deafness and loss of dentition.
Defects in TNFRSF11A are a cause of Paget disease of bone type 2 (PDB2) [MIM:602080]; also known as familial Paget disease of bone. PDB2 is a bone-remodeling disorder with clinical similarities to FEO. Unlike FEO, however, affected individuals have involvement of the axial skeleton with lesions in the spine, pelvis and skull.
Defects in TNFRSF11A are the cause of osteopetrosis autosomal recessive type 7 (OPTB7) [MIM:612301]; also called osteoclast-poor osteopetrosis with hypogammaglobulinemia. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. OPTB7 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development. OPTB7 is associated with hypogammaglobulinemia.
Sequence similaritiesContains 4 TNFR-Cys repeats.
- Information by UniProt
- CD 265 antibody
- CD265 antibody
- FEO antibody
ab200369 has been referenced in 7 publications.
- Mao Z et al. MicroRNA-155 inhibition up-regulates LEPR to inhibit osteoclast activation and bone resorption via activation of AMPK in alendronate-treated osteoporotic mice. IUBMB Life N/A:N/A (2019). PubMed: 31317664
- Ding LZ et al. Mangiferin inhibits apoptosis and oxidative stress via BMP2/Smad-1 signaling in dexamethasone-induced MC3T3-E1 cells. Int J Mol Med 41:2517-2526 (2018). PubMed: 29484386
- Chen X et al. RANKL signaling in bone marrow mesenchymal stem cells negatively regulates osteoblastic bone formation. Bone Res 6:34 (2018). PubMed: 30510839
- Huang Y et al. Molecular mechanisms of the inhibitory effects of jiangu granule-containing serum on RANKL-induced osteoclastogenesis. Mol Med Rep 16:8420-8426 (2017). PubMed: 28983609
- Kirschenbaum A et al. Prostatic Acid Phosphatase Alters the RANKL/OPG System and Induces Osteoblastic Prostate Cancer Bone Metastases. Endocrinology 157:4526-4533 (2016). PubMed: 27783536
- Xing R et al. Interleukin-21 promotes osteoclastogenesis in RAW264.7 cells through the PI3K/AKT signaling pathway independently of RANKL. Int J Mol Med 38:1125-34 (2016). PubMed: 27599586
- Li XJ et al. Bergapten exerts inhibitory effects on diabetes-related osteoporosis via the regulation of the PI3K/AKT, JNK/MAPK and NF-?B signaling pathways in osteoprotegerin knockout mice. Int J Mol Med N/A:N/A (2016). WB ; Mouse . PubMed: 27840967